February 25, 2026: Supplement – ASH Meeting Highlights 2025   (View All Issues)

Leukemia

Lymphoma

Julia Cipriano, MS, CMPP  / February 25, 2026: Supplement – ASH Meeting Highlights 2025

Pirtobrutinib Improves Progression-Free Survival vs Bendamustine/Rituximab in Front-Line CLL/SLL

The first prospective, randomized phase III trial of a noncovalent Bruton’s tyrosine kinase (BTK) inhibitor exclusively in treatment-naive patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)—BRUIN CLL-313—demonstrated a statistically significant and clinically...

Leukemia

Caroline Helwick  / February 25, 2026: Supplement – ASH Meeting Highlights 2025

Benefit of Azacitidine Plus Venetoclax Confirmed in AML

The combination of the hypomethylating agent azacitidine and the BCL2 inhibitor venetoclax is an established regimen in older, unfit patients with acute myeloid leukemia (AML). Now, a phase II randomized trial indicates potential for less intensive therapy in the newly diagnosed fit population. In...